Yi Zhang

Dr. Yi Zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
XJXin Jin
Xin Jin
JKJanne Kaes
Janne Kaes
JSJan Van Slambrouck
Jan Van Slambrouck
Ilhan InciIlhan Inci
Ilhan Inci
SAStephan Arni
Stephan Arni
LCLaurens J Ceulemans
Laurens J Ceulemans
Lung transplantation improves the outcome and quality of life of patients with end-stage pulmonary disease. However, the procedure is still hampered by the lack of suitable donors, the complexity of the surgery, and the risk of developing chronic lung allograft dysfunction. Over the past decades, translational experiments in animal models have led to a better understanding of physiology and immunopathology following the lung transplant procedure. Small animal models (e.g., rats and mice) are mostly used in experiments regarding immunology and pathobiology and are preferred over large animal models due to the ethical aspects, the cost–benefit balance, and the high throughput possibility. In this comprehensive review, we summarize the reported surgical techniques for lung transplantation in rodent models and the management of perioperative complications. Furthermore, we propose a guide to help identify the appropriate species for a given experiment and discuss recent experimental findings in small animal lung transplant models.

2 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
TZTeng Zhao
Teng Zhao
MWMingchao Wang
Mingchao Wang
XZXin Zhao
Xin Zhao
SWShuang Weng
Shuang Weng
KQKun Qian
Kun Qian
YZYi Zhang
Yi Zhang
Objective: YTH domain family 2 (YTHDF2) is an important N6-methyladenosine (m6A) reader, but its role in lung adenocarcinoma remains elusive. This study assessed its function in lung adenocarcinoma.Methods: YTHDF2 expression in lung adenocarcinoma was explored using public databases, such as The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumour Analysis Consortium (CPTAC). The effect of YTHDF2 on a lung adenocarcinoma cell line was explored by performing cytological and molecular experiments. Molecules downstream of YTHDF2 were identified using proteomics, and the related pathways were verified through cytological and molecular biology experiments.Results: YTHDF2 expression was upregulated in lung adenocarcinoma, and patients with high YTHDF2 expression experienced prolonged overall survival. In two lung cancer cell lines, YTHDF2 knockdown inhibited proliferation but promoted migration, invasion, and the epithelial-mesenchymal transition. The proteomic analysis identified 142 molecules downstream of YTHDF2, and 11 were closely related to survival. Further experiments revealed that YTHDF2 inhibited expression of the family with sequence similarity 83D (FAM83D)-TGFβ1-SMAD2/3 pathway components. This study is the first to show that YTHDF2 regulated the downstream TGFβ1-SMAD2/3 pathway through FAM83D in lung adenocarcinoma.Conclusion: YTHDF2 inhibits the migration and invasion of lung adenocarcinoma cells by regulating the FAM83D-TGFβ1-pSMAD2/3 pathway, which may play an important role in lung cancer metastasis.

26 February 2024 in Thoracic Cancer
Verified
Journal Article
Open access
XTXiaoru Tian
Xiaoru Tian
XLXingsheng Liu
Xingsheng Liu
KWKai Wang
Kai Wang
RWRuotian Wang
Ruotian Wang
YLYuanbo Li
Yuanbo Li
YZYi Zhang
Yi Zhang
Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer (NSCLC).Methods: We enrolled 58 NSCLC patients in a real‐world setting, and 58 tumor tissues and 325 plasma samples were analyzed. Tumor tissues and plasma samples were subjected to targeted next‐generation sequencing (NGS) of 1021 cancer‐related and ultra‐deep targeted NGS covering 338 genes, respectively.Results: ctDNA was detected in 31.0% of cases at the first postoperative time, which was associated with advanced tumor stage, T stage and KEAP1 or GRIN2A mutations in tissues. ctDNA positivity at landmark and longitudinal indicated the shorter disease‐free survival. For patients with ctDNA positivity at the first postoperative time, regardless of adjuvant therapy, all patients who were persistently ctDNA positive during postoperative surveillance had disease recurrence. Among the patients who were ctDNA negative, only two patients (15.4%, 2/13) receiving adjuvant therapy relapsed, while one patient (50.0%, 1/2) without adjuvant therapy relapsed. For the first postoperative ctDNA negative patients, the recurrence rate of patients with adjuvant therapy was and higher than without adjuvant therapy (22.6% [7/31] vs. 11.1% [1/9]). The patients who became ctDNA positive may also benefit from intervention therapy.Conclusion: Postoperative ctDNA is a prognostic marker, and ctDNA‐detection may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

21 August 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YZYi Zhang
Yi Zhang
KQKun Qian
Kun Qian
XLXingsheng Liu
Xingsheng Liu
XZXin Zhao
Xin Zhao
TZTeng Zhao
Teng Zhao
GLGaojun Lu
Gaojun Lu

1 April 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
KSKejian Shi
Kejian Shi
JAJiajia An
Jiajia An
KQKun Qian
Kun Qian
XZXin Zhao
Xin Zhao
FLFeng Li
Feng Li
YZYi Zhang
Yi Zhang

14 October 2021 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
KHKe Han
Ke Han
JWJukun Wang
Jukun Wang
KQKun Qian
Kun Qian
TZTeng Zhao
Teng Zhao
YZYi Zhang
Yi Zhang
Purpose: ADME genes are those involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs. In the present study, a non-small-cell lung cancer (NSCLC) risk prediction model was established using prognosis-associated ADME genes, and the predictive performance of this model was evaluated and verified. In addition, multifaceted difference analysis was performed on groups with high and low risk scores. Methods: An NSCLC sample transcriptome and clinical data were obtained from public databases. The prognosis-associated ADME genes were obtained by univariate Cox and lasso regression analyses to build a risk model. Tumor samples were divided into high-risk and low-risk score groups according to the risk score. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of the differentially expressed genes and the differences in the immune infiltration, mutation, and medication reactions in the two groups were studied in detail. Results: A risk prediction model was established with seven prognosis-associated ADME genes. Its good predictive ability was confirmed by studies of the model's effectiveness. Univariate and multivariate Cox regression analyses showed that the model’s risk score was an independent prognostic factor for patients with NSCLC. The study also showed that the risk score closely correlated with immune infiltration, mutations, and medication reactions. Conclusion: The risk prediction model established with seven ADME genes in the present study can predict the prognosis of patients with NSCLC. In addition, significant differences in immune infiltration, mutations, and therapeutic efficacy exist between the high- and low-risk score groups.